Currently Viewing:
The Academy of Managed Care Pharmacy (AMCP) Nexus 2018
Drug Market to See More Competition, Launch of Biosimilars in 2019
October 23, 2018
Dr Aimee Tharaldson Outlines Current Key Market Trends in Specialty Pharmacy
October 23, 2018
Dr Jane F. Barlow: How Curative, High-Cost Therapies Bring Challenges to the Reimbursement Landscape
October 23, 2018
Law to Curb Opioid Abuse Will Have Many Managed Care Priorities, Experts Say
October 23, 2018
Analysis Finds HIV Therapy Biktarvy Associated With Cost Savings Compared With Most Regimens
October 24, 2018
Dr Christopher Diehl Explains the Pharmacist's Role in Value-Based Models
October 24, 2018
Dr Jennifer Graff on Using Real-World Evidence to Deliver High-Quality Care
October 24, 2018
CMS Audits Give View Into How Well Health Plans Deliver Medicare Programs
October 24, 2018
Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS
October 25, 2018
Dan Mendelson: Healthcare Policy Changes Avalere Health Is Paying Attention To
October 25, 2018
Dr Kibum Kim on Precision Medicine in Managed Care
October 25, 2018
Currently Reading
From Pathways to Pharmacy: Sharing Approaches to Value-Based Care
October 25, 2018
Dr Aimee Tharaldson: Recently Approved Specialty Drugs, Upcoming Approvals to Watch For
November 13, 2018
Dan Mendelson Discusses How Mergers and Acquisitions Are Affecting the Market
November 14, 2018
Dan Mendelson on the Trump Administration's Efforts to Lower Drug Prices
November 22, 2018
Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies
November 27, 2018
Dan Mendelson's Expectations for Cross-Sector Mergers Like CVS, Aetna
November 28, 2018
Specialty Drug Approvals Dr Aimee Tharaldson is Looking Out for in 2019
November 29, 2018
Dan Mendelson on the Shift to Value-Based Care and Prescribing Patterns
December 22, 2018

From Pathways to Pharmacy: Sharing Approaches to Value-Based Care

Mary Caffrey
A new session at the Academy for Managed Care Pharmacy Nexus 2018 allowed for sharing ideas that have recently been put into practice.
Andrew Hertler, MD, FACP, presented a strategy for implementing a value-based clinical pathway in oncology, which he said is helping a Florida practice select high-value regimens that save payers money—without giving up margins that cost the practice.

The “buy and bill” method that historically sustained oncology practices is giving way to value-based strategies as the cost of treatments escalate. Physicians once were paid a percentage of the cost of the therapy, but payers now look for ways to encourage practices to embrace low-cost options while giving patients the best evidence-based medicine. As Hertler illustrated, in this system, a payer can reimbursement the practice the same amount by encouraging the practice to use a lower-cost treatment that works just as well—a biosimilar, for example. But the payer saves by spending less on the therapy itself.

How does the oncologist know what to select? It’s all built into clinical pathway software that gives the practice choices, Hertler said. In the sample he shared, the US Oncology–affiliated practice saved 14.4% on the average Medicare Advantage member medication cost, and received a $152,000 bonus. Goals were met or exceeded in most cancer types, except bladder cancer.

As has been found elsewhere, a champion is essential. “We had one physician leader,” Hertler said. “This would have been more difficult without him being willing to buy into this.”

Data and feedback are important as well. Doctors are “all above average,” and do not like being the outlier. When they first see they are, they tend to question the data before self-examination occurs. But eventually, it happens.

Maggie Alston, CHFP, of Milliman in New York, New York, offered advice on a pair of overlooked elements of value-based contracts: patient attribution and risk modeling. Defining these items upfront is extremely important, she said, yet they are often overlooked until partners are far along in the process. The ability to define the patient universe is so critical, she said, that an inability to do so may mean that some contracts simply can’t be done, if administrative burden is so high that the potential savings just are not there.

When setting out to start a contract process, Alston recommends getting many people involved—actuaries, data scientists—a diverse team is needed. “Be ready to think outside the box,” she said.

Patient attribution is important because it’s so directly tied to any contract that addresses adherence. Patients can stop taking drugs for many reasons, and there are so many ways to measure how patients take drugs. Knowing who the patients are is key. “Medicaid patients are much sicker than those in a clinical trial,” and this will affect the outcome of the contract.

Paying attention to sample size is critical, too. If it’s too small, the pharmaceutical company could be at risk, Alston said.

Most of all, she encouraged drug makers to stay engaged and keep talking to payers. Most are willing to listen if ideas are reasonable. “They want your opinion and want you to be actively engaged. Payers rarely want things one way and ‘That’s it.’”

But if there’s no deal to be had, Alston said, “Know when to walk away.”

Related Articles

Horizon BCBSNJ Reports 10% Rise in Value-Based Payments
Value-Based Payment Success Hinges on a Holistic Strategy for Changes
Dr Christopher Diehl Explains the Pharmacist's Role in Value-Based Models
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up